Plus Therapeutics Stock Today
| PSTV Stock | USD 0.56 0.05 9.80% |
PerformanceWeakest
| Odds Of DistressRisky
|
Plus Therapeutics is selling for under 0.56 as of the 4th of January 2026; that is 9.80 percent increase since the beginning of the trading day. The stock's lowest day price was 0.52. Plus Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 6th of October 2025 and ending today, the 4th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of November 2000 | Category Healthcare | Classification Health Care |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. The company has 137.43 M outstanding shares of which 7.07 M shares are at this time shorted by private and institutional investors with about 1.1 trading days to cover. More on Plus Therapeutics
Moving against Plus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Plus Stock Highlights
| CEO President | MD MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsPlus Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Plus Therapeutics' financial leverage. It provides some insight into what part of Plus Therapeutics' total assets is financed by creditors.
| |||||
Plus Therapeutics (PSTV) is traded on NASDAQ Exchange in USA and employs 21 people. Plus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 76.27 M. Plus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 137.43 M outstanding shares of which 7.07 M shares are at this time shorted by private and institutional investors with about 1.1 trading days to cover.
Plus Therapeutics currently holds about 20.27 M in cash with (10.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Plus Therapeutics Probability Of Bankruptcy
Ownership AllocationPlus Therapeutics owns a total of 137.43 Million outstanding shares. Roughly 94.8 pct. of Plus Therapeutics outstanding shares are held by general public with 1.4 % owned by insiders and only 3.8 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Plus Ownership Details
Plus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Atlantic Union Bankshares Corp | 2025-06-30 | 500 | |
| Wells Fargo & Co | 2025-06-30 | 357 | |
| Tradewinds Capital Management, Llc | 2025-06-30 | 200 | |
| Bank Of America Corp | 2025-06-30 | 158 | |
| Advisor Group Holdings, Inc. | 2025-06-30 | 133 | |
| Jones Financial Companies Lllp | 2025-06-30 | 26.0 | |
| Susquehanna International Group, Llp | 2025-06-30 | 0.0 | |
| Aigh Capital Management, Llc | 2025-03-31 | 0.0 | |
| Barclays Plc | 2025-06-30 | 0.0 | |
| Jane Street Group Llc | 2025-06-30 | 117.5 K | |
| Ubs Group Ag | 2025-06-30 | 87.6 K |
Plus Therapeutics Historical Income Statement
Plus Stock Against Markets
Plus Therapeutics Corporate Management
| John Fraser | Chief Scientist | Profile | |
| Gary CPA | Advisor | Profile | |
| MS MBA | Executive Strategy | Profile | |
| Marc MD | CEO Pres | Profile | |
| Desiree Smith | Principal Controller | Profile |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.